Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

被引:38
|
作者
Gamsjaeger, Sonja [1 ]
Buchinger, Birgit [1 ]
Zoehrer, Ruth [1 ]
Phipps, Roger [2 ]
Klaushofer, Klaus [1 ]
Paschalis, Eleftherios P. [1 ]
机构
[1] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, WGKK & AUVA Trauma Ctr Meidling, Dept Med 1, A-1140 Vienna, Austria
[2] Procter & Gamble Pharmaceut, Mason, OH USA
关键词
Teriparatide; Alendronate; Risedronate; Bone material properties; Fourier transform infrared imaging; Raman Microspectroscopy; Mineral maturity; Collagen cross-links; ILIAC CREST BIOPSIES; FTIR MICROSPECTROSCOPIC ANALYSIS; PARATHYROID-HORMONE; AMERICAN-SOCIETY; MINERAL DENSITY; TASK-FORCE; QUALITY; OSTEONECROSIS; JAW; HYDROXYAPATITE;
D O I
10.1016/j.bone.2011.08.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present work we examined the effect of teriparatide administration following bisphosphonate treatment on bone compositional properties by Raman and Fourier Transform Infrared Imaging (FTIR) microspectroscopic analysis. Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed at anatomical areas of similar tissue age in bone forming areas (within the fluorescent double labels). The outcomes that were monitored and reported were mineral to matrix ratio (corresponding to ash weight), mineral maturity (indicative of the mineral crystallite chemistry and stoichiometry, and having a direct bearing on crystallite shape and size), relative proteoglycan content (regulating mineralization commencement), and the ratio of two of the major enzymatic collagen cross-links (pyridinoline/divalent). Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment. Moreover differences between ALN and RIS treated patients at baseline in the collagen cross-link ratio were observed. Since tissue areas of similar tissue age were analyzed, these differences may not be attributed to differences in bone turnover. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1160 / 1165
页数:6
相关论文
共 50 条
  • [21] Early Effects of Denosumab in Postmenopausal Women with Low Bone Mineral Density Previously Treated with Alendronate
    Brown, J. P.
    Kendler, D. L.
    Benhamou, C. L.
    Lillestol, M.
    Roux, C.
    Siddhanti, S.
    Man, H. S.
    Martin, J. San
    Bone, H. G.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (12): : 3973 - 3974
  • [22] APPLICATION OF QUANTITATIVE BONE SCAN USING KBONE VALUES FOR THE ASSESSMENT OF REGIONAL BONE METABOLISM IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN TREATED EITHER WITH ALENDRONATE OR TERIPARATIDE
    Dixit, V.
    Parida, G.
    Sen, S.
    Sati, H.
    Kumar, R.
    Malhotra, R.
    Garg, B.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S432 - S432
  • [23] EFFECTS OF ODANACATIB ON BMD AND SAFETY IN POSTMENOPAUSAL WOMEN PREVIOUSLY TREATED WITH ALENDRONATE
    De Villiers, Tobie
    Bonnick, Sydney
    Odio, Alberto
    Palacios, Santiago
    Chapurlat, Roland
    Scott, Boyd
    De Tilleghem, Celine Le Bailly
    Leung, Albert
    Gurner, Deborah
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S36 - S37
  • [24] Vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate: The role of pre-treatment bone turnover
    Seibel, MJ
    Barton, I
    Grauer, A
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S20 - S20
  • [25] Effects of Odanacatib On BMD and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
    Chapurlat, Roland
    Bonnick, Sydney
    De Villiers, Tobias
    Odio, Alberto
    Palacios, Santiago
    Scott, Boyd
    De Tilleghem, Celine Le Bailly
    DaSilva, Carolyn
    Leung, Albert
    Gurner, Deborah
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S312 - S312
  • [26] EFFECTS OF ODANACATIB ON BMD AND OVERALL SAFETY IN THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN PREVIOUSLY TREATED WITH ALENDRONATE
    Smith, E.
    Chapurlat, R.
    Bonnick, S.
    De Villiers, T.
    Odio, A.
    Palacios, S.
    Scott, B.
    De Tilleghem, Le Bailly C.
    Dasilva, C.
    Leung, A.
    Gurner, D.
    INTERNAL MEDICINE JOURNAL, 2013, 43 : 29 - 29
  • [27] EFFECTS OF ODANACATIB ON BMD AND OVERALL SAFETY IN THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN PREVIOUSLY TREATED WITH ALENDRONATE
    Chen, J-F
    De Villiers, T.
    Bonnick, S.
    Chapurlat, R.
    Odio, A.
    Palacios, S.
    Scott, B.
    De Tilleghem, C. Le Bailly
    DaSilva, C.
    Leung, A.
    Gurner, D.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S753 - S754
  • [28] Differences in early dynamics of serum bone markers in women with postmenopausal osteoporosis treated by alendronate or risedronate
    Sferrazza, C
    Napoli, N
    Cannone, V
    Cusumano, G
    Rini, G
    Di Fede, G
    BONE, 2005, 36 : S422 - S423
  • [29] DIFFERENCES IN EARLY DYNAMICS OF SERUM BONE MARKERS IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS TREATED BY ALENDRONATE OR RISEDRONATE
    Sferrazza, C.
    Carmina, E.
    Cannone, V.
    Avila, D.
    Sutera, L.
    Rini, G. B.
    Di Fede, G.
    CALCIFIED TISSUE INTERNATIONAL, 2004, 74 : S97 - S97
  • [30] Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women
    Tonino, RP
    Meunier, PJ
    Emkey, R
    Rodriguez-Portales, JA
    Menkes, CJ
    Wasnich, RD
    Bone, HG
    Santora, AC
    Wu, M
    Desai, R
    Ross, PD
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (09): : 3109 - 3115